Restarting etentamig therapy after dosing delays or interruptions: Population pharmacokinetics (PopPK) and PK/PD simulations and supporting clinical data
Observational analysis predicts etentamig safe for resuming therapy without repriming in RRMM patients, indicating potential for extended dosing delays.
Key Points
Treatment interruption for etentamig in multiple myeloma patients can last up to 16 weeks without needing to restart the step-up dose.
Predicted IL-6 levels post-dosing delays were lower than those observed with the standard regimen, supporting therapy safety.
Population pharmacokinetic simulations showed that etentamig concentrations remain above the threshold for at least 16 weeks, aiding therapeutic management.
Cyokine release syndrome was not recurrent in patients experiencing dosing delays, suggesting tolerability of extended treatment interruptions.